227 related articles for article (PubMed ID: 28855352)
1. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Hills R; Gallimore A; Godkin A
Clin Cancer Res; 2017 Nov; 23(22):6771-6780. PubMed ID: 28855352
[No Abstract] [Full Text] [Related]
2. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
3. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
[TBL] [Abstract][Full Text] [Related]
6. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
Zheng L; Edil BH; Soares KC; El-Shami K; Uram JN; Judkins C; Zhang Z; Onners B; Laheru D; Pardoll D; Jaffee EM; Schulick RD
Ann Surg Oncol; 2014 Nov; 21(12):3931-7. PubMed ID: 24943235
[TBL] [Abstract][Full Text] [Related]
7. OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Lai C; August S; Albibas A; Behar R; Cho SY; Polak ME; Theaker J; MacLeod AS; French RR; Glennie MJ; Al-Shamkhani A; Healy E
Clin Cancer Res; 2016 Aug; 22(16):4236-48. PubMed ID: 27034329
[TBL] [Abstract][Full Text] [Related]
8. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C; Thiery-Vuillemin A; Calcagno F; Legros A; Simonin H; Boullerot L; Jacquin M; Nguyen T; Mouillet G; Borg C; Adotévi O
Int J Cancer; 2020 Aug; 147(4):1199-1205. PubMed ID: 31749145
[TBL] [Abstract][Full Text] [Related]
9. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
[TBL] [Abstract][Full Text] [Related]
10. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.
Tada K; Kitano S; Shoji H; Nishimura T; Shimada Y; Nagashima K; Aoki K; Hiraoka N; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Yamada Y; Katayama N; Boku N; Heike Y; Hamaguchi T
Cancer Immunol Res; 2016 Jul; 4(7):592-9. PubMed ID: 27197061
[TBL] [Abstract][Full Text] [Related]
12. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs.
Zhao Y; Wang S; Lv S; Liu X; Li W; Song Y; Rong D; Zheng P; Huang H; Zheng H
Sci Rep; 2024 Jun; 14(1):13432. PubMed ID: 38862586
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.
Bonertz A; Weitz J; Pietsch DH; Rahbari NN; Schlude C; Ge Y; Juenger S; Vlodavsky I; Khazaie K; Jaeger D; Reissfelder C; Antolovic D; Aigner M; Koch M; Beckhove P
J Clin Invest; 2009 Nov; 119(11):3311-21. PubMed ID: 19809157
[TBL] [Abstract][Full Text] [Related]
14. Effector memory T cells, early metastasis, and survival in colorectal cancer.
Pagès F; Berger A; Camus M; Sanchez-Cabo F; Costes A; Molidor R; Mlecnik B; Kirilovsky A; Nilsson M; Damotte D; Meatchi T; Bruneval P; Cugnenc PH; Trajanoski Z; Fridman WH; Galon J
N Engl J Med; 2005 Dec; 353(25):2654-66. PubMed ID: 16371631
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C; Filipazzi P; Tazzari M; Casati C; Beretta V; Pilla L; Patuzzo R; Maurichi A; Cova A; Maio M; Chiarion-Sileni V; Tragni G; Santinami M; Vergani B; Villa A; Berti E; Umansky L; Beckhove P; Umansky V; Parmiani G; Rivoltini L; Castelli C
Cancer Immunol Immunother; 2013 May; 62(5):897-908. PubMed ID: 23589107
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
[TBL] [Abstract][Full Text] [Related]
18. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
